Trial Profile
A Phase II Study of Erlotinib for previously treated Non-Small Cell Lung Cancer Patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2010
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Dec 2010 New trial record